Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: A study of the Chronic Malignancies Working Party of EBMT

The results of an analysis of 346 patients with CALR-mutated myelofibrosis who received allogeneic hematopoietic cell transplantation (allo-HCT) demonstrated OS rates, at median 40 months follow-up, at 1, 3, and 5 years of 81%, 71%, and 63%, respectively. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, and the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Further, a comparative analysis between patients with CALR- and JAK2-mutated disease showed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival in the CALR-mutated group.